Showing results (2471-2480 of 2,814) with videos related to

Sort By:
Pageof 282
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2020
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant MelanomaCharles Marusak, Varsha Thakur, Yuan Li, et al.
JAMA Oncology|March 25, 2021
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ Randall Patrinely, Rebecca Johnson, Aleigha R Lawless, et al.
Cancer Discovery|May 16, 2012
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantationOliver Weigert, Nadja Kopp, Andrew A Lane, et al.
Vaccines|November 24, 2022
Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPsCourtney L Finch, Thomas H King, Kendra J Alfson, et al.
Oncoimmunology|February 25, 2021
A multicenter characterization of hepatitis associated with immune checkpoint inhibitorsJ Randall Patrinely, Ben McGuigan, Sunandana Chandra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 StudyAdnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Journal for Immunotherapy of Cancer|January 19, 2023
Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritisMeghan E Sise, Qiyu Wang, Harish Seethapathy, et al.
Neurobiology of Aging|June 30, 2021
DNA methylation in the TNF-alpha gene decreases along with aging among delirium inpatientsTakehiko Yamanashi, Taku Saito, Tong Yu, et al.
Cell|September 11, 2018
Extracellular Matrix Remodeling Regulates Glucose Metabolism through TXNIP DestabilizationWilliam J Sullivan, Peter J Mullen, Ernst W Schmid, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Pageof 282